Patent ID: 7514229
Filing Date: 2009-04-07
Classification: C12Q,G01N

Abstract:
1. A method of staging a blood disorder comprising: combining a hematologic sample from a patient suspected of having a blood disorder selected from the group consisting of polycythemia vera (PV); chronic myelogenous leukemia (CML); essential thrombocythemia (ET); acute myelogenous leukemia (AML); chronic myelomonocytic leukemia (CMML); post-polycythemic myeloid metaplasia (PPMM); and angiogenic myeloid metaplasia with myelofibrosis (AMM) with specific binding members that are sufficient to distinguish the distribution of hematopoietic stem and progenitor cell subsets between hematopoietic stem cells (HSC); common myeloid progenitors (CMP); megakaryocyte erythroid progenitors (MEP; granulocyte macrophage progenitors (GMP), wherein said binding members include at least one of CD47, IL-3Rα and CD45RA; and determining the distribution of hematopoietic stem and progenitor cells between said subsets; wherein the distribution of hematopoietic stem and progenitor cells is indicative of the phenotype of said blood disorder.